These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36757170)

  • 41. Long-term event-free survival, chimerism and fertility outcomes in 234 patients with sickle-cell anemia younger than 30 years after myeloablative conditioning and matched-sibling transplantation in France.
    Bernaudin F; Dalle JH; Bories D; de Latour RP; Robin M; Bertrand Y; Pondarre C; Vannier JP; Neven B; Kuentz M; Maury S; Lutz P; Paillard C; Yakouben K; Thuret I; Galambrun C; Dhedin N; Jubert C; Rohrlich P; Bay JO; Suarez F; Raus N; Vernant JP; Gluckman E; Poirot C; Socié G;
    Haematologica; 2020 Jan; 105(1):91-101. PubMed ID: 31097628
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recent advances in the understanding of inherited sideroblastic anaemia.
    Camaschella C
    Br J Haematol; 2008 Oct; 143(1):27-38. PubMed ID: 18637800
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of 5-aminolevulinic acid on erythropoiesis: a preclinical in vitro characterization for the treatment of congenital sideroblastic anemia.
    Fujiwara T; Okamoto K; Niikuni R; Takahashi K; Okitsu Y; Fukuhara N; Onishi Y; Ishizawa K; Ichinohasama R; Nakamura Y; Nakajima M; Tanaka T; Harigae H
    Biochem Biophys Res Commun; 2014 Nov; 454(1):102-8. PubMed ID: 25450364
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Three siblings with variable degrees of neuromuscular involvement and congenital sideroblastic anemia: A peculiar phenotype and a surprise genotypic explanation.
    Salam MAE; Salama K; Selim YMM; Saad M; Rady R; Alawbathani S; Schroeder S; Elmonem MA; Elkhateeb N
    Ann Hum Genet; 2023 Jul; 87(4):166-173. PubMed ID: 36916508
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Allogenic hematopoietic stem cell transplantation in an Iranian patient with osteopetrosis caused by carbonic anhydrase II deficiency: A case report.
    Shamsian BS; Momtazmanesh N; Saneifard H; Tabatabaei SMTH; Jafari M; Pour ZK; Al-Hussieni KJMR; Jamee M; Kamfar S
    Pediatr Transplant; 2024 May; 28(3):e14689. PubMed ID: 38655726
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Radiation-free reduced-intensity hematopoietic stem cell transplantation with in vivo T-cell depletion from matched related and unrelated donors for Fanconi anemia: prognostic factor analysis.
    Rostami T; Mousavi SA; Kiumarsi A; Kasaeian A; Rad S; Yaghmaie M; Ghavamzadeh A; Mousavi SA
    Exp Hematol; 2022 May; 109():27-34. PubMed ID: 35202716
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Allogeneic hematopoietic stem cell transplantation in aplastic anemia: current indications and transplant strategies.
    Iftikhar R; Chaudhry QUN; Anwer F; Neupane K; Rafae A; Mahmood SK; Ghafoor T; Shahbaz N; Khan MA; Khattak TA; Shamshad GU; Rehman J; Farhan M; Khan M; Ansar I; Ashraf R; Marsh J; Satti TM; Ahmed P
    Blood Rev; 2021 May; 47():100772. PubMed ID: 33187812
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Treatment of Gaucher disease with allogeneic hematopoietic stem cell transplantation: report of three cases and review of literatures].
    Tang X; Luan Z; Wu N; Zhang B; Jing Y; Du H; Lu W; Xu S
    Zhonghua Er Ke Za Zhi; 2015 Nov; 53(11):810-6. PubMed ID: 26758318
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Allogeneic peripheral stem cell transplantation in a case of hereditary sideroblastic anaemia.
    González MI; Caballero D; Vázquez L; Cañizo C; Hernández R; López C; Izarra A; Arroyo JL; González M; García R; San Miguel JF
    Br J Haematol; 2000 Jun; 109(3):658-60. PubMed ID: 10886220
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
    Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
    Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Molecular pathophysiology of sideroblastic anemia].
    Fujiwara T
    Rinsho Ketsueki; 2018; 59(10):1979-1987. PubMed ID: 30305500
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Hematopoietic stem-cell transplantation in aplastic anemia].
    Hernández-Rivera EG
    Rev Invest Clin; 2005; 57(2):298-304. PubMed ID: 16524071
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Outcomes of allogeneic hematopoietic stem cell transplantation for 18 patients with paroxysmal nocturnal haemoglobinuria].
    Chen F; Wu D; Tang X; Miao M; Fu C; Qiu H; Jin Z; Xue S; Ma X; Sun A; Chang W; Ruan C
    Zhonghua Xue Ye Xue Za Zhi; 2015 Dec; 36(12):1005-10. PubMed ID: 26759101
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term follow up after allogeneic stem cell transplantation in patients with severe aplastic anemia after cyclophosphamide plus antithymocyte globulin conditioning.
    Konopacki J; Porcher R; Robin M; Bieri S; Cayuela JM; Larghero J; Xhaard A; Andreoli AL; Dhedin N; Petropoulou A; Rodriguez-Otero P; Ribaud P; Moins-Teisserenc H; Carmagnat M; Toubert A; Chalandon Y; Socie G; Peffault de Latour R
    Haematologica; 2012 May; 97(5):710-6. PubMed ID: 22180425
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1.
    Marsh RA; Bleesing JJ; Chandrakasan S; Jordan MB; Davies SM; Filipovich AH
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1641-5. PubMed ID: 24923536
    [TBL] [Abstract][Full Text] [Related]  

  • 58. X-linked sideroblastic anemia associated with a novel ALAS2 mutation and unfortunate skewed X-chromosome inactivation patterns.
    Aivado M; Gattermann N; Rong A; Giagounidis AA; Prall WC; Czibere A; Hildebrandt B; Haas R; Bottomley SS
    Blood Cells Mol Dis; 2006; 37(1):40-5. PubMed ID: 16735131
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Congenital sideroblastic anemia: a report of two cases.
    Gupta SK; Rao S; Kar R; Tyagi S; Pati HP
    Indian J Pathol Microbiol; 2009; 52(3):424-6. PubMed ID: 19679982
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fludarabine-based reduced intensity regimen for matched related donor hematopoietic stem cell transplantation in acquired severe aplastic anemia.
    Ghanem KM; Kharfan-Dabaja MA; El-Solh H; Harris N; Kreidieh N; Nehme R; Muwakkit SA; Saab R; Bazarbachi A; Abboud MR
    Curr Res Transl Med; 2017 Sep; 65(3):115-119. PubMed ID: 28988743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.